Wall Street Zen Upgrades SAB Biotherapeutics (NASDAQ:SABS) to “Hold”

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts have also commented on the stock. Leerink Partnrs upgraded shares of SAB Biotherapeutics to a “strong-buy” rating in a report on Wednesday, September 17th. Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, November 17th. Leerink Partners assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, September 17th. They set an “outperform” rating and a $7.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SAB Biotherapeutics in a report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

SAB Biotherapeutics Trading Up 3.9%

Shares of SABS stock opened at $3.95 on Friday. The business has a 50-day moving average of $2.76 and a 200 day moving average of $2.31. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $6.60. The stock has a market capitalization of $188.06 million, a PE ratio of -1.28 and a beta of 0.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.38. As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SABS. ADAR1 Capital Management LLC bought a new stake in shares of SAB Biotherapeutics during the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics in the third quarter worth about $32,000. Virtu Financial LLC purchased a new stake in SAB Biotherapeutics in the third quarter worth about $40,000. HB Wealth Management LLC boosted its position in SAB Biotherapeutics by 10.9% during the 1st quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after acquiring an additional 25,800 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $5,730,000. 7.82% of the stock is currently owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.